Ask AI

Emerging CELMoD Strategies in DLBCL and FL: Interpreting the Data and Preparing for Practice

Text Module
Text Module Start Activity
This activity is available for 0.75 CME/CE credit(s).

Released: September 21, 2026

Expiration: March 20, 2027

See Activity Collection

Through this certified text module, dive into the emerging role of CELMoDs in lymphoma with a focus on golcadomide in B-cell lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. Learners will explore the mechanism of action of CELMoDs, evolving clinical evidence across frontline and relapsed/refractory settings, combination strategies with chemoimmunotherapy and immune-directed therapies, and practical considerations for patient selection, treatment sequencing, and management of treatment-related adverse events.

CELMoDs in DLBCL and FL

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with lymphoma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following best reflects the biological rationale for investigating golcadomide in B-cell lymphomas?

How confident are you in your answer?
4.

You are educating your team about golcadomide in preparation for managing patients who may be treated with this agent. Which of the following would you explain to them is the most common grade ≥3 adverse event (AE) associated with golcadomide? 

How confident are you in your answer?
5.

Which of the following most accurately captures the disease settings in which golcadomide has shown preliminary clinical activity, either alone or in combination?

How confident are you in your answer?